- Home
- INCR vs ADAG Comparison
INCR vs ADAG Comparison
Compare INCR & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INCR
- ADAG
- Stock Information
- Founded
- INCR 1994
- ADAG 2011
- Country
- INCR Israel
- ADAG China
- Employees
- INCR N/A
- ADAG N/A
- Industry
- INCR Biotechnology: Pharmaceutical Preparations
- ADAG Biotechnology: Pharmaceutical Preparations
- Sector
- INCR Health Care
- ADAG Health Care
- Exchange
- INCR Nasdaq
- ADAG Nasdaq
- Market Cap
- INCR 84.5M
- ADAG 91.4M
- IPO Year
- INCR N/A
- ADAG 2021
- Fundamental
- Price
- INCR $1.55
- ADAG $1.92
- Analyst Decision
- INCR
- ADAG Strong Buy
- Analyst Count
- INCR 0
- ADAG 1
- Target Price
- INCR N/A
- ADAG $8.00
- AVG Volume (30 Days)
- INCR 24.4K
- ADAG 51.2K
- Earning Date
- INCR 08-15-2025
- ADAG 07-24-2025
- Dividend Yield
- INCR N/A
- ADAG N/A
- EPS Growth
- INCR N/A
- ADAG N/A
- EPS
- INCR N/A
- ADAG N/A
- Revenue
- INCR $65,575,323.00
- ADAG $103,204.00
- Revenue This Year
- INCR $69.54
- ADAG $6,488.89
- Revenue Next Year
- INCR $41.75
- ADAG $57.50
- P/E Ratio
- INCR N/A
- ADAG N/A
- Revenue Growth
- INCR N/A
- ADAG N/A
- 52 Week Low
- INCR $1.17
- ADAG $1.33
- 52 Week High
- INCR $2.62
- ADAG $3.58
- Technical
- Relative Strength Index (RSI)
- INCR 60.11
- ADAG 56.78
- Support Level
- INCR $1.48
- ADAG $1.74
- Resistance Level
- INCR $1.56
- ADAG $1.98
- Average True Range (ATR)
- INCR 0.06
- ADAG 0.12
- MACD
- INCR 0.01
- ADAG -0.00
- Stochastic Oscillator
- INCR 80.99
- ADAG 72.22
About INCR Intercure Ltd.
Intercure Ltd is engaged in the research, cultivation, production, and distribution of pharma-grade cannabis-based products. Its products are available in dried inflorescences or liquid oil form, and are marketed through various brands, including Pharmo Cann, Humboldt, Indoor, Space Labs, Canndoc Utopia, Binske, Canndoc Stars, and others. The company has two operating segments, namely Investments in portfolio companies in the biomed sector and Investments in the medical cannabis sector. A majority of its revenue is generated from the Cannabis segment.
About ADAG Adagene Inc.
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.